CELEX: 32022M10574
Language: en
Date: 2022-02-22 00:00:00
Title: Commission Decision of 22/02/2022 declaring a concentration to be compatible with the common market (Case No COMP/M.10574 - ADVENT / CALDIC) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                                 Brussels, 22.02.2022
                                                                 C(2022) 1217 final
                                                                                 PUBLIC VERSION
                                                                 Advent International Corporation
                                                                 800 Boylston Street, Suite 3300
                                                                 MA 02199-8069 Boston
                                                                 United States of America
Subject:        Case M.10574 - ADVENT / CALDIC
                Commission decision pursuant to Article 6(1)(b) of Council Regulation
                (EC) No 139/20041 and Article 57 of the Agreement on the European
                Economic Area2
Dear Sir or Madam,
1.      On 31 January 2022, the European Commission received notification of a proposed
        concentration pursuant to Article 4 of the Merger Regulation by which Advent
        International Corporation and/or its affiliates (“Advent”, USA) acquire within the
        meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of
        Caldic Holdco B.V. (“Caldic”, the Netherlands). The concentration is accomplished
        by way of purchase of shares.3
2.      The business activities of the undertakings concerned are:
              Advent is a private equity investor based in Boston, USA, focusing on the
                 acquisition of equity stakes and the management of investment funds in
                 various sectors, including industrial, technology, retail, consumer and leisure,
                 healthcare, and business and financial services,
              Caldic is an international provider of value-add life sciences and specialty
                 chemicals solutions serving customers in the life science and industrial sectors.
3.      After examination of the notification, the European Commission has concluded that
        the notified operation falls within the scope of the Merger Regulation and of
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
3       Publication in the Official Journal of the European Union No C 66, 08.02.2022, p. 61.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak---    paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004.4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                  For the Commission
                                                  (Signed)
                                                  Olivier GUERSENT
                                                  Director-General
4  OJ C 366, 14.12.2013, p. 5.
                                             2